Stockholders Approve Significant Expansion of Equity Incentive Plan
ACRV sits 32% above its 52-week low of $1.15 on light trading volume (0.3× avg).
Summary
Acrivon Therapeutics' stockholders approved a significant expansion of the company's equity incentive plan, increasing the share reserve by 3 million shares and introducing an evergreen provision, which could lead to substantial future dilution.
Key Events · Financing and Capital Events · ACRV
-
Equity Incentive Plan Approved
Stockholders approved the Amended and Restated 2022 Equity Incentive Plan at the annual meeting on June 17, 2026.
-
Significant Share Reserve Increase
The plan increases the aggregate number of shares available for equity awards by 3,000,000, bringing the total to 8,606,723 shares. This represents a substantial potential dilution of existing shareholder value.
-
Evergreen Provision Included
The plan includes an automatic annual increase of 5% of the company's fully diluted shares through 2032, adding to the long-term dilutive potential.
-
Annual Meeting Results
Stockholders also re-elected Michael Tomsicek and Charles Baum as Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.
Analysis · ACRV · Life Sciences
Acrivon Therapeutics' stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the shares available for equity awards by 3,000,000 to a total of 8,606,723 shares. This approval finalizes the proposal previously disclosed in a DEFA14A filing on May 22, 2026. This substantial increase in the share reserve, coupled with an evergreen provision for annual 5% increases, represents significant potential dilution for existing shareholders. The total shares authorized under the plan are equivalent to over 20% of the company's current outstanding shares, creating a considerable overhang on the stock.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.4% of the 1168 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRV was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.1M. The 52-week trading range was $1.15 to $3.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.